Humanigen Inc (HGENQ)

[cowtown jay]

I've talked about an $8.5B market cap as being a conservative estimate for Humanigen. When we were naively thinking that LIVE-AIR's phenomenally successful trial outcome would result in an EUA, and could yield a market cap in the $20B range, we had reason to think that.

Novavax had attained that level.

https://www.macrotrends.net/stocks/charts/NVAX/novavax/market-cap

Moderna did even better.

https://www.macrotrends.net/stocks/charts/MRNA/moderna/market-cap

Neither of those companies were much bigger than Humanigen before covid.

Probably within just the last six months, we have seen pandemic-level outbreaks in both China and Japan. Japan has reported that the virus does not seem to respond to any of the available treatments. They are hoping that a vaccine can be developed for this variant within the next month or so. Meanwhile, ICU's in major metropolitan areas are maxed out.

There is an irrefutable requirement for governments to be prepared to prevent and treat new covid infections. It is beginning to appear that lenz can do both, as a cocktail as well as a therapeutic.

So if there are 110M more shares currently in our market than the company has issued, I don't think I was out of line in asking the company to start the bidding for those shares at $201. That would give us a market cap starting at about $24B.

And we have more than just covid for our pipeline, including the $26B asthma market, and the $60B arthritis market, plus those indications I mentioned in this thread already.

https://www.precedenceresearch.com/press-release/asthma-treatment-market#:~:text=The%20global%20asthma%20treatment%20market,forecast%20period%202023%20To%202032.

https://www.globenewswire.com/en/news-release/2023/02/10/2605710/0/en/Trending-Global-Rheumatoid-Arthritis-Drugs-Market-Size-Share-to-Hit-70-1-Billion-by-2030-at-a-1-75-CAGR-Growing-cases-of-rheumatoid-arthritis-to-propel-market-demand-Facts-Factors.html